In animal models of focal cerebral ischemia, hypothermia might reduce the infarct volume by up to 90%. 1, 23 Initial clinical studies showed that moderate hypothermia seems to be effective in the treatment of acute hemispheric infarction. 18 Measurements of CBF, AVDO 2 , and CMRO 2 during hypothermia were made in animal models with controversial results, 16 as well as in patients with severe head injuries, 11, 19 and during cardiopulmonary bypass surgery. 4 No clinical studies have yet been performed in patients with ischemic infarction during hypothermia. Initial studies in 12 patients with severe MCA territory infarction (seven patients treated with hypothermia, four with decompressive surgery) indicated that bedside monitoring of CBF may give prognostic information on outcome and may guide therapy for elevated ICP in patients with malignant hemispheric infarction. The aim of the present study was to assess the influence of moderate hypothermia on CBF and O 2 metabolism in patients with severe MCA infarction.
midazolam, and they received a neuromuscular block (atracurium 0.3-0.6 mg/kg/hr).
Measurement Parameters
The following data were prospectively recorded: ICP was monitored ipsilaterally to the affected hemisphere by using intraparenchymatous sensors and transducers (Codman microsensor; Johnson & Johnson, Raynham, MA).
The mean arterial blood presure, ICP, and cerebral perfusion pressure, as the difference between mean arterial blood pressure and ICP, were monitored continuously. With each CBF measurement blood gas level analysis from the arterial site and the jugular bulb were performed.
The CBF and CMRO 2 measurements were estimated by using a new double-indicator dilution method. 8 Two fiberoptic thermistor No. 5 French catheters (PV-2024; Pulsion-Medizintechnik, Munich, Germany) were placed in the thoracic aorta via a femoral artery port and in the jugular bulb by retrograde cannulation of the dominant internal jugular vein. The dominant internal jugular vein was identified by duplex sonography. To avoid extracerebral contamination, correct positioning of the jugular bulb catheter tip was verified on x-ray films after injection of 1 ml Omnipaque. Bolus injections of ice-cold indocyanine green (20 mg, 40 ml, Ͻ 5 °C) were administered via a 12-gauge central venous line. The resulting thermo dilution and dye dilution curves were recorded digitally (Z 021 and IVH5; Pulsion COLD Medical Systems, Munich, Germany). The CBF was measured by calculating the mean transit times of the cold bolus and dye. Thermodilution and dye dilution curves were rejected if the following artifacts were identified: thermal drift in the baseline, wall artifacts by the jugular bulb catheter, or insufficient result of curve fitting because of respiratory artifacts induced by mechanical ventilation. Values of CBF less than 25 ml/100g/min were calculated from a corresponding long mean transit time of more than 240 seconds, which cannot be measured precisely for the highly diffusible indicator negative heat. The CMRO 2 was calculated from the product of CBF and AVDO 2 . The series of CBF measurements were made to baseline value during normothermia, immediately before hypothermia was induced, after induction of hypothermia when the target body core temperature of 33 to 34°C was reached, at the end of hypothermia before rewarming, and after rewarming during normothermia.
Induction of Hypothermia
Moderate hypothermia was induced using cooling blankets (Bair Hugger; Augustine Medical, St Prairie; Minnesota) with cool ventilator air to fanning the patient's body surface. The core body temperature was kept between 33°C and 34°C for 48 to 96 hours. After a decrease in the signs of brain edema, patients were rewarmed passively. Foley catheters with a temperature resolution of 0.1°C were used for monitoring core body temperature in the bladder (Mon-a-therm; Mallinckrodt, Hennef/Sieg, Germany). The room temperature in the intensive care unit was maintained between 18°C and 20°C.
RESULTS
Moderate hypothermia was induced in six patients during a mean period of 63.5 hours (range 49-86 hours). Table 1 gives the intervals in hours between onset of symptoms and the series of CBF measurements. In six patients, 19 CBF measurements and jugular bulb O 2 saturation values were obtained (Table 2) . Absolute values for CBF varied from less than 25 (below the methodological limit of measurement) to 84 ml/100g/min and for CMRO 2 from less than 1.13 (below the methodologic limit of measurement) to 3.45 ml/100g/min. In two patients with pupillary disturbances hypothermia was initiated as quickly as possible. Therefore baseline ICP, CBF, AVDO 2 , and CMRO 2 were not measured in these two patients during E. Keller, et al. normothermia, and in one patient measurement was not obtained during early hypothermia. Two patients died during rewarming due to intractable intracranial hypertension. No measurements after rewarming could be obtained in these two cases.
In this preliminary study, only a small number of patients were studied in whom there were high interindividual variabilities in the time intervals to initiation of hypothermia as well as in absolute CBF and CMRO 2 values. Median values for these patients were not calculated. Therefore the measurements obtained during the different phases of hypothermia are given for each patient separately in Table 2 and in Fig. 1 .
After induction of hypothermia, elevated ICP could be controlled in all patients. During early hypothermia, CBF decreased in all patients (Fig. 1) . During late hypothermia, CBF recovered in the three patients who survived but remained diminished in those two patients who eventually died. In all but one patient, CMRO 2 was reduced during all phases of hypothermia (Fig. 1) . The diminished CMRO 2 , as the product of CBF and AVDO 2 , can be explained during early hypothermia by the drop in CBF and during late hypothermia by the reduction in AVDO 2 (five of six patients). The AVDO 2 increased in four of five patients during early hypothermia and decreased markedly in all but those two patients who died during late hypothermia (Fig. 1) .
DISCUSSION
The results of animal and clinical studies have shown that hypothermia has the potential to limit the extent of secondary brain damage. 5, 10, 11, 19 The protective effects of hypothermia have been described to be a consequence of lowering high ICP, 11, 12, 18, 19 suppressing the extracellular concentrations of excitatory neurotransmitters, 11 stabilizing cell membranes, 21 slowing the depletion of brain energy stores, 20 and improving the O 2 supply and demand relationship by reducing cerebral metabolism. 13 Maher and Hachinski 10 concluded that one of the most important mechanisms of hypothermia is that the decrease in cerebral O 2 consumption is more pronounced than the decline in CBF, resulting in apparent luxury perfusion. Hypothermia may also lower the minimum amount of CBF necessary to maintain cell viability and, by this and other mechanisms, expand the ischemic penumbra surrounding the infarct. 1 In animals the effect of artificial hypothermia on cerebral O 2 metabolism 2 and CBF 17 were investigated more than 40 years ago. In uninjured dogs, Rosomoff 15, 16 demonstrated that CBF decreased 6.7% with a similar decrease in CMRO 2 by reducing body temperature by 1°C. The author further assessed the protective effect of hypothermia in a canine model of permanent MCA occlusion and evaluated the beneficial effects of preinjury or immediate postinjury hypothermia. Busto, et al., 3 assessed hypothermia-induced changes in the microvascular blood flow during global ischemia. The authors demonstrated in rats that local CBF was not affected during mild to moderate intraischemic hypothermia in any group. On the other hand, in a rabbit model of focal cerebral ischemia, Lo and Steinberg 9 demonstrated that moderate hypothermia (30°C) decreases significantly cortical blood flow but not blood flow in other brain areas. This effect was not seen at either 37 or 33°C.
To our knowledge no studies of CBF and CMRO 2 measurements have been performed in patients with ischemic infarction during hypothermia treatment. Our preliminary observations in six patients with severe hemispheric infarction indicate that CBF may decrease immediately after induction of hypothermia. During late hypothermia CBF seems to recover in patients who survive but remains diminished in patients who die. In addition, AVDO 2 increased in most patients during early hypothermia and decreased in all but those patients who died during late hypothermia. The CMRO 2 level is diminished during early hypothermia as a consequence of CBF reduction and during late hypothermia by the diminished AVDO 2 .
Metz, et al., 12 reported a significant decrease in CMRO 2 in 10 patients with severe brain injury which was caused
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Hypothermia in severe cerebral artery infarction 3 Fig. 1 . Values are shown for CBF (ml/100g/min) (a), CMRO 2 (ml/100g/min) (b), and AVDO 2 (ml/dl) (c) during normothermia, after induction of hypothermia (early hypothermia), at the end of hypothermia before rewarming (late hypothermia), and after rewarming during normothermia. Immediately after induction of hypothermia CBF decreased in all patients. During late hypothermia CBF recovered in patients who survived but decreased or remained diminished in two patients who died. In all but one patient, CMRO 2 was reduced during all phases of hypothermia. Levels of AVDO 2 increased in four of five patients during early hypothermia and decreased markedly in all but those patients who died during late hypothermia.
by reduced cerebral O 2 extraction. In contrast to our measurements, the authors observed no CBF changes during early hypothermia. Marion, et al., 11 measured CBF by using the 133 Xe technique in 20 hypothermia-treated patients; they described a decline in CBF by approximately 5.2 ml/100g/min per 1°C reduction in body temperature. Shiozaki, et al., 19 performed CBF measurements using the hydrogen clearance method in five patients with severe head injury and found a mean decrease of 15.4 ml/100g/min in CBF and 1 ml/100 ml in AVDO 2 2 hours after induction of hypothermia.
It is possible that CBF may be influenced by different causes of primary brain damage and timing of induction of hypothermia. Furthermore, initial experience with CBF monitoring in patients with severe hemispheric infarction showed that critical rises in ICP were accompanied by decreased CBF values as well. 8 Positron emission tomography findings showed that severe partial ischemia with impaired neuronal function without causing irreversible neuronal damage frequently persists for up to 24 hours and occasionally even up to 72 hours. This was demonstrated by an elevated regional O 2 extraction in the presence of a relative preservation of the rate of regional O 2 metabolism and a low regional CBF. 22 According to our experience CBF measurements during early hypothermia were performed 83 hours in the mean after onset of symptoms of ischemic stroke. Therefore, increased AVDO 2 and decreased CBF during early hypothermia could be a consequence of changes in cerebral hemodynamics during ischemic stroke itself and may not be induced by hypothermia. Additionally, different methods of CBF measurement may contribute to the discrepancies in the literature. The double-indicator dilution technique used in our studies allowed global CBF measurements, whereas the 133 Xe technique, applied in the study by Metz, et al., 12 estimates cortical CBF.
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CONCLUSIONS
Moderate hypothermia in severe MCA infarction reduced CMRO 2 during all phases and CBF during early hypothermia. During late hypothermia, CBF recovered in patients who eventually had good outcomes but remained diminished in those patients who died. Further studies in which the results from a normothermia group are compared are needed to clarify the influence of hypothermia independent from the CBF measurement technique and from other factors characterizing the course of the illness of ischemic stroke.
